Molecular Determinants of Sotorasib Efficacy in Patients with Advanced KRASG12C-mutated NSCLC By Ogkologos - June 6, 2025 658 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from integrated analyses of sotorasib clinical efficacy biomarkers in the CodeBreaK 100 and CodeBreaK 200 studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR New Safety Signal for Use of Ibrutinib in Combination with Rituximab... September 15, 2021 France Bans all Textured and Polyurethane Breast Implants Amid BIA-ALCL Cancer... April 5, 2019 Favourable Benefit-Risk Profile of Trastuzumab Deruxtecan in Patients with HER2-positive MBC... May 10, 2023 Facing Crisis After Crisis During Cancer: How to Cope April 28, 2022 Load more HOT NEWS Selumetinib Continues to Show Promise in Children with NF1 New tool to tackle gaps in public’s knowledge of blood cancer... What to Know About Biomarker Testing for Lung Cancer: An Expert... 2021 ASCO Annual Meeting: Immunotherapy for Melanoma and Non-Small Cell Lung Cancer,...
